Curasight 관리

관리 기준 확인 2/4

Curasight CEO는 Ulrich Krasilnikoff, Jan2016 에 임명되었습니다 의 임기는 8.83 년입니다. 는 DKK 45.18M 가치에 해당하는 회사 주식의 19.25% 직접 소유합니다. 45.18M. 경영진과 이사회의 평균 재임 기간은 각각 8.8 년과 8.8 년입니다.

주요 정보

Ulrich Krasilnikoff

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	8.8yrs
CEO 소유권	19.2%
경영진 평균 재임 기간	8.8yrs
이사회 평균 재임 기간	8.8yrs

최근 관리 업데이트

Recent updates

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

Aug 29

CEO

Ulrich Krasilnikoff (57 yo)

8.8yrs

테뉴어

Mr. Ulrich Alexander Krasilnikoff has been Chief Executive Officer, Chief Financial Officer and Executive Director at Curasight A/S since 2016. Mr. Krasilnikoff served as an Associate Partner at Capidea Ma...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ulrich Krasilnikoff	CEO, CFO & Executive Director	8.8yrs	데이터 없음	19.25% DKK 45.2m
Jacob Madsen	Co-Founder & Director CMC	11.8yrs	데이터 없음	4.4% DKK 10.3m
Andreas Kjaer	Co-Founder	11.8yrs	데이터 없음	29.09% DKK 68.3m
Hanne Jensen	Chief Development Officer & COO	2.8yrs	데이터 없음	0.19% DKK 451.6k
Nic Gillings	Head of Quality Assurance & Regulatory Affairs	3.4yrs	데이터 없음	데이터 없음

8.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: CURAS 의 관리팀은 노련하고 경험 (평균 재직 기간 8.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ulrich Krasilnikoff	CEO, CFO & Executive Director	8.8yrs	데이터 없음	19.25% DKK 45.2m
Andreas Kjaer	Co-Founder	11.8yrs	데이터 없음	29.09% DKK 68.3m
Kirsten Drejer	Chairman of the Board	3.4yrs	데이터 없음	0.019% DKK 45.2k
Lars Trolle	Independent Deputy Chairman of the Board	10.8yrs	데이터 없음	2.84% DKK 6.7m
Charlotte Vedel	Independent Deputy Chairman of the Board	4.8yrs	데이터 없음	0.19% DKK 451.6k

8.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: CURAS 의 이사회는 경험(평균 재직 기간 8.8 년)으로 간주됩니다.

Curasight 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Curasight A/S Announces Board Changes

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S, Annual General Meeting, Mar 24, 2022

Recent updates

Curasight A/S Announces Clinical Supply Agreement with Curium for uTREAT® Development and Commercialization

Curasight A/S Announces International Patent Application for uTREAT® to Broaden IP Protection

Curasight A/S Publishes Clinical Phase II Trial of uPAR-PET in Brain Cancer Patients; Data Supports Development of uTREAT for Brain Cancer

New major risk - Financial position

Curasight A/S to Report Q3, 2024 Results on Nov 21, 2024

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

New minor risk - Shareholder dilution

Curasight A/S to Report Q2, 2024 Results on Aug 22, 2024

Curasight A/S to Report Q3, 2024 Results on Jul 02, 2024

New major risk - Share price stability

New major risk - Financial position

Curasight A/S to Report Q1, 2024 Results on May 23, 2024

Less than half of directors are independent

Curasight A/S Announces Approval of Clinical Trial Application (CTA) for Phase 2 Trial with uTRACE in Prostate Cancer Patients

Curasight A/S Announces Board Changes

Curasight A/S has withdrawn its Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S has filed a Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S to Report Fiscal Year 2023 Results on Feb 22, 2024

Curasight Gears Up for Phase II Study in Prostate Cancer

Curasight A/S to Report Q3, 2023 Results on Nov 24, 2023

New minor risk - Share price stability

Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer (NSCLC)

Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S to Report Q2, 2023 Results on Aug 24, 2023

Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer

Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)

Curasight A/S to Report Fiscal Year 2022 Results on Feb 23, 2023

Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors

Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer

Curasight A/S, Annual General Meeting, Mar 24, 2022

Curasight A/S Announces Positive Data of uTREAT® in Glioblastoma Provides "Green Light" to Proceed with Next Steps

New 90-day high: kr.41.50

New 90-day high: kr.34.45

Curasight Announces Results from Phase II Study in Prostate Cancer to Be Published in the Journal of Nuclear Medicine

Curasight A/S to Report Q1, 2021 Results on May 20, 2021

Curasight A/S Initiates Pre-Clinical Study on Therapy in Brain Cancer and Signs CRO-Agreement

Curasight A/S has completed an IPO in the amount of DKK 32.688 million.

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령